国产吉西他滨联合铂类进行非小细胞肺癌化疗的生存状况观察  

Survival conditions of patients with non-small cell lung cancer after chemotherapy of domestic gemcitabine combined with platinum

作　　者：郑庆锋[1,2,3] 王宇昭[1,2,3] 吴楠[1,2,3] 陈晋峰[1,2,3] 张力建[1,2,3] 杨跃[1,2,3] 

机构地区：[1]北京大学临床肿瘤学院 [2]北京肿瘤医院 [3]北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室胸外二科,北京100142

出　　处：《中国新药杂志》2011年第4期347-349,375,共4页Chinese Journal of New Drugs

摘　　要：目的:评价国产吉西他滨联合铂类治疗非小细胞肺癌患者的生存状况。方法:60例非小细胞肺癌患者根据是否进行根治性手术,将本组患者分为晚期化疗组和根治性手术治疗+化疗组。晚期化疗组22例,根治性手术治疗+化疗组38例。采用国产吉西他滨联合顺铂/卡铂方案,化疗方案采用常规剂量及用法,每3周为1周期,所有患者至少完成2周期化疗。对所有患者均进行随访,分别评估2组生存状况。结果:晚期化疗组中22例患者化疗2周期后疗效为:1例CR,8例PR,13例SD。治疗有效率(CR+PR)为40.9%。晚期化疗组患者1年生存率44.0%,中位生存期12.39个月。根治性手术治疗组1年生存率89.0%,3年生存率80.0%,中位生存期48.0个月。结论:国产吉西他滨与铂类联合方案治疗非小细胞肺癌用药安全有效,生存状况同国外文献同类药物报道相似。Objective： To evaluate the survival after treatment with domestic gemcitabine（Yu Jie） combined with platinum in patients with non-small cell lung cancer.Methods： In 60 patients with non-small cell lung cancer,according to whether radical surgery,the patients were divided into advanced chemotherapy group（n=22） and radical surgery plus chemotherapy group（n=38）.One cycle chemotherapy of gemcitabine combined with cisplatin/carboplatin was performed every 3 weeks,and all patients completed 2 cycles of chemotherapy at least.All patients were followed up,and survival conditions in two groups were evaluated.Results： The incidence of other adverse effects was lower.In 22 patients in advanced chemotherapy group,1 patient was CR,8 were PR,and 13 were SD after 2 cycles of chemotherapy.The effective rate（CR＋PR） was 40.9%.After advanced chemotherapy,1-year survival was 44.0%,and median survival was 12.39 months.After radical surgery group,1 year survival rate was 89.0%,3-year survival was 80.0%,and median survival was 48.0 months.Conclusion： Domestic gemcitabine combined with a platinumr is of good safety,effect and survival,similar to those reported in the literature at abroad,in the treatment of non-small cell lung cance.

关 键 词：非小细胞肺癌 吉西他滨 铂类 

分 类 号：R734.2[医药卫生—肿瘤]